Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients.
Glucocorticosteroids (GS) are standard treatment of multiple sclerosis (MS) relapse, but no superiority of any commonly used doses is known. The aim of present study was to evaluate mRNA expression for two cytokines: IL-6 and IL-8. Ethylenediaminetetraacetic acid blood samples from 35 MS relapse patients were obtained before therapy, after 7, 14 days, and 3 months from treatment start (500 versus 1000 mg for 5 days). Significant neurological improvement measured with EDSS was independent to GS dose. Changes of mRNA cytokines expression were more evident in higher dose group but for IL-6 mainly in females.
Mirowska-Guzel
Dagmara
D
2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Gromadzka
Grazyna
G
Kurowska
Katarzyna
K
Czlonkowski
Andrzej
A
Czlonkowska
Anna
A
D000328:Adult; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000097:blood; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000097:blood; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000096:biosynthesis*; D012008:Recurrence; D012737:Sex Factors
D005938:Glucocorticoids; D015850:Interleukin-6; D016209:Interleukin-8; D018696:Neuroprotective Agents; D012333:RNA, Messenger; D008775:Methylprednisolone